Van As, Nicholas John
Tree, Alison
Ostler, Peter James
van der Voet, Hans
Ford, Daniel
Tolan, Shaun
Wells, Paula
Mahmood, Rana
Winkler, Mathias
Chan, Andrew
Thompson, Alan
Ogden, Christopher
Brown, Stephanie
Pugh, Julia
Burnett, Stephanie M.
Griffin, Clare
Patel, Jaymini
Naismith, Olivia
Hall, Emma
Clinical trials referenced in this document:
Documents that mention this clinical trial
TROG 18.01 phase III randomised clinical trial of the Novel Integration of New prostate radiation schedules with adJuvant Androgen deprivation: NINJA study protocol
https://doi.org/10.1136/bmjopen-2019-030731
Need for Consensus When Prescribing Stereotactic Body Radiation Therapy for Prostate Cancer
https://doi.org/10.1016/j.ijrobp.2014.09.025
Dose-escalation of five-fraction SABR in prostate cancer: Toxicity comparison of two prospective trials
https://doi.org/10.1016/j.radonc.2015.12.020
Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: Toxicity, biochemical, and pathological outcomes
https://doi.org/10.1016/j.radonc.2013.03.022
PACE-A: An international phase 3 randomised controlled trial (RCT) comparing stereotactic body radiotherapy (SBRT) to surgery for localised prostate cancer (LPCa)—Primary endpoint analysis.
https://doi.org/10.1200/jco.2023.41.6_suppl.298
A comparative study of quality of life in patients with localized prostate cancer treated at a single institution: Stereotactic ablative radiotherapy or external beam+high dose rate brachytherapy boost
https://doi.org/10.1016/j.radonc.2014.10.013
Funding for this research was provided by:
Accuray
The Royal Marsden Cancer Charity
Varian
Publication History
Published: 2023-02-21